25-Hydroxycholesterol Regulates Lysosomal AMPK Activation and Macrophage Immunometabolism

Study Background and Research Question

Tumor-associated macrophages (TAMs) are abundant within the tumor microenvironment (TME), where they exert profound effects on tumor progression. Their phenotypic plasticity allows them to either promote inflammation and antitumor responses or, conversely, to adopt immunosuppressive functions that facilitate tumor growth and immune evasion. Recent research has spotlighted abnormal cholesterol and oxysterol metabolism in the TME, but the mechanisms by which these metabolites modulate TAM behavior have remained elusive. Xiao et al. (2024) addressed the critical question: How does the oxysterol 25-hydroxycholesterol (25HC) influence the activation state and metabolic programming of TAMs, and what are the implications for antitumor immunity?

Key Innovation from the Reference Study

The key innovation presented by Xiao et al. is the identification of a lysosome-centered signaling axis in TAMs, where accumulated 25HC activates AMPKα via a GPR155-mTORC1 pathway. This activation leads to direct phosphorylation of STAT6 at Ser564, enhancing its transcriptional activity and promoting the production of immunosuppressive mediators such as arginase 1 (ARG1). These findings position cholesterol-25-hydroxylase (CH25H) and its product 25HC as central immunometabolic checkpoints within the TME, with tangible impacts on the polarization and function of TAMs.

Methods and Experimental Design Insights

The authors combined single-cell RNA sequencing (scRNA-seq), genetic mouse models, biochemical assays, and functional immune profiling to dissect this pathway. Key methodological highlights include:

• scRNA-seq analysis: Used to identify TAM subsets with high CH25H expression, which correlated with reduced patient survival across cancer types.
• Genetic ablation: Ch25h-deficient mice and macrophages were generated to test the functional consequences of loss of 25HC synthesis.
• Metabolic and signaling assays: Lysosomal localization of 25HC was verified, and its competitive binding to GPR155 (a lysosomal GPCR) was characterized. Downstream mTORC1 inhibition and subsequent AMPKα activation were quantified by phosphorylation status.
• Phosphoproteomics and immunoblotting: Used to confirm direct phosphorylation of STAT6 by AMPKα at Ser564, a modification critical for ARG1 induction.
• In vivo tumor models: Tumor growth and immune infiltration were assessed in wild-type and Ch25h-deficient backgrounds, with or without anti-PD-1 immunotherapy.

Core Findings and Why They Matter

The study's major findings can be summarized as follows:

• 25HC accumulation in TAMs: Elevated CH25H expression in TAMs leads to pronounced accumulation of 25HC within lysosomes. This subset is enriched in immunosuppressive macrophages, as confirmed by scRNA-seq and patient data analyses (Xiao et al., 2024).
• AMPKα activation via GPR155-mTORC1: 25HC competes with cholesterol for binding to the lysosomal GPCR GPR155, resulting in inhibition of mTORC1 and subsequent activation of AMPKα. This mechanistic link integrates cholesterol metabolism with metabolic pathway regulation in macrophages.
• STAT6 phosphorylation and immunosuppressive programming: Activated AMPKα directly phosphorylates STAT6 at Ser564, which amplifies STAT6 transcriptional activity and drives ARG1 expression—an established marker of pro-tumor, immunosuppressive macrophages.
• Therapeutic implications: Deletion or inhibition of CH25H in macrophages reduces their immunosuppressive function, increases tumor-infiltrating T cell activation, and sensitizes tumors (even otherwise "cold" tumors) to anti-PD-1 immune checkpoint therapy. This demonstrates that targeting this axis can reshape the TME in favor of antitumor immunity.

These results have broad implications for immunometabolic research, including acute myeloid leukemia (AML), where metabolic reprogramming and apoptosis induction in immune and tumor cells are critical for therapeutic response.

Comparison with Existing Internal Articles

Several internal analyses (e.g., Precision AMPK Agonist for Functional Metabolic Reprogramming in AML) highlight the importance of precise AMP-activated protein kinase (AMPK) modulation in both metabolic pathway research and acute myeloid leukemia models. Unlike prior focus on direct AMPK agonists such as GSK621, which enables targeted activation of AMPK substrates and robust apoptosis induction in AML cell lines, the reference study by Xiao et al. uncovers an endogenous, disease-relevant regulatory loop mediated by oxysterol signaling. This bridges the gap between pharmacological activation (as demonstrated by GSK621’s substrate specificity and potency) and physiological/pathological AMPK regulation by tumor-intrinsic metabolites.

Furthermore, the reference study's elucidation of the interplay between AMPKα, mTORC1, and STAT6 extends existing discussions of autophagy promotion and fatty acid oxidation enhancement—mechanisms also connected to AMPK agonist research in metabolic and immunological contexts (see internal review).

Limitations and Transferability

While the study provides compelling mechanistic insights, several limitations should be considered:

• Model specificity: Most findings are based on murine models and in vitro macrophage systems. While human scRNA-seq data support the relevance of CH25Hhi TAMs across cancers, direct clinical translation requires further validation.
• Context dependence: The immunometabolic effects of 25HC and CH25H deletion may differ across tumor types and microenvironments. Not all tumors may exhibit the same oxysterol/TAM axis activity.
• Targeting challenges: Pharmacological targeting of CH25H or downstream effectors in humans remains in early stages, and off-target metabolic consequences are possible.

Nevertheless, the demonstration that modulating this pathway can synergize with existing immunotherapies (e.g., anti-PD-1) highlights its translational promise.

Protocol Parameters

• CH25H knockout strategy: For functional validation, use CRISPR/Cas9-mediated deletion in macrophage lines or employ Ch25h-/- mice for in vivo tumor studies.
• 25HC loading: Incubate macrophages with 25HC at concentrations (e.g., 10 μM) validated to induce lysosomal accumulation and downstream signaling, monitoring cell viability and phenotype as controls.
• AMPK pathway interrogation: Assess AMPKα phosphorylation status at T172 and downstream effectors (e.g., ULK1, ACC) using Western blot or phospho-specific antibodies.
• Immunophenotyping: Quantify ARG1 and other immunosuppressive markers by flow cytometry or qPCR following experimental manipulations.
• Synergy with immunotherapy: For translational studies, combine CH25H modulation with anti-PD-1 therapy in established tumor models; monitor tumor growth, T cell infiltration, and survival endpoints.

Research Support Resources

To experimentally probe AMPK-dependent metabolic reprogramming in cancer or immunology workflows, researchers can employ potent, specific AMPK agonists. GSK621 (SKU B6020) from APExBIO is a well-characterized tool compound, supporting robust activation of AMPK and downstream targets in both cell-based and in vivo assays, as described in internal comparative reviews. Its validated efficacy in apoptosis induction and autophagy promotion in AML and other models makes it a valuable resource for mechanistic studies aligned with the pathways characterized by Xiao et al.